167 related articles for article (PubMed ID: 37053535)
21. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
22. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
24. Phase II Study of Copanlisib in Patients With Tumors With
Damodaran S; Zhao F; Deming DA; Mitchell EP; Wright JJ; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Suga JM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2022 May; 40(14):1552-1561. PubMed ID: 35133871
[TBL] [Abstract][Full Text] [Related]
25. In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.
Piaggio F; Croce M; Reggiani F; Monti P; Bernardi C; Ambrosio M; Banelli B; Dogrusöz M; Jockers R; Bordo D; Puzone R; Viaggi S; Coviello D; Lanza FB; Bartolucci M; Petretto A; Mosci C; Gangemi R; van der Velden PA; Jager MJ; Pfeffer U; Amaro A
Eur J Cancer; 2022 Jul; 170():27-41. PubMed ID: 35580369
[TBL] [Abstract][Full Text] [Related]
26. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
[TBL] [Abstract][Full Text] [Related]
27. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
28. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
Koopmans AE; Vaarwater J; Paridaens D; Naus NC; Kilic E; de Klein A;
Br J Cancer; 2013 Jul; 109(2):493-6. PubMed ID: 23778528
[TBL] [Abstract][Full Text] [Related]
29. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
30. Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.
Ayturk UM; Couto JA; Hann S; Mulliken JB; Williams KL; Huang AY; Fishman SJ; Boyd TK; Kozakewich HP; Bischoff J; Greene AK; Warman ML
Am J Hum Genet; 2016 Apr; 98(4):789-95. PubMed ID: 27058448
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
32. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
[TBL] [Abstract][Full Text] [Related]
33. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
34. Trametinib Induces the Stabilization of a Dual
Krebs FS; Gérard C; Wicky A; Aedo-Lopez V; Missiaglia E; Bisig B; Trimech M; Michielin O; Homicsko K; Zoete V
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126538
[TBL] [Abstract][Full Text] [Related]
35. Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.
Bender RP; McGinniss MJ; Esmay P; Velazquez EF; Reimann JD
Mod Pathol; 2013 Oct; 26(10):1320-8. PubMed ID: 23599145
[TBL] [Abstract][Full Text] [Related]
36. GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma.
Liau JY; Tsai JH; Lan J; Chen CC; Wang YH; Lee JC; Huang HY
Virchows Arch; 2020 Mar; 476(3):475-481. PubMed ID: 31707589
[TBL] [Abstract][Full Text] [Related]
37. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of primary uveal melanoma: results of a Polish cohort.
Kowalik A; Karpinski P; Markiewicz A; Orlowska-Heitzman J; Romanowska-Dixon B; Donizy P; Hoang MP
Melanoma Res; 2023 Apr; 33(2):104-115. PubMed ID: 36719926
[TBL] [Abstract][Full Text] [Related]
39. Iris and Ciliary Body Melanocytomas Are Defined by Solitary GNAQ Mutation Without Additional Oncogenic Alterations.
Solomon DA; Ramani B; Eiger-Moscovich M; Milman T; Uludag G; Crawford JB; Phan I; Char DH; Shields CL; Eagle RC; Bastian BC; Bloomer MM; Pekmezci M
Ophthalmology; 2022 Dec; 129(12):1429-1439. PubMed ID: 35835335
[TBL] [Abstract][Full Text] [Related]
40. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
